MARKET

SYRE

SYRE

Spyre Therapeutics
NASDAQ
88.98
+1.73
+1.98%
After Hours: 88.98 0 0.00% 19:30 09/04 EDT
OPEN
86.45
PREV CLOSE
87.25
HIGH
89.18
LOW
84.68
VOLUME
803.86K
TURNOVER
--
52 WEEK HIGH
110.18
52 WEEK LOW
14.51
MARKET CAP
7.85B
P/E (TTM)
-38.3171
1D
5D
1M
3M
1Y
5Y
1D
Should Spyre Therapeutics’ RA Proof‑of‑Mechanism but Pipeline Reprioritization Reshape SYRE’s Autoimmune Strategy?
Simply Wall St · 7h ago
Spyre Therapeutics Announces Grants of Inducement Awards
Barchart · 18h ago
Weekly Report: what happened at SYRE last week (0824-0828)?
Weekly Report · 4d ago
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)
TipRanks · 6d ago
Weekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal
NASDAQ · 08/28 14:42
Spyre Therapeutics: Catalyst-Rich Period But Easiest Money May Have Been Made (Downgrade)
Seeking Alpha · 08/27 13:06
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)
TipRanks · 08/27 11:20
Spyre Therapeutics Is Maintained at Buy by Deutsche Bank
Dow Jones · 08/26 18:11
More
About SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).

Webull offers Spyre Therapeutics Inc stock information, including NASDAQ: SYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYRE stock methods without spending real money on the virtual paper trading platform.